Abstracts tagged "seronegative spondyloarthropathy and spondylarthritis"

Abstract Number: 699 • 2018 ACR/ARHP Annual Meeting
New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Silvia Tamanini¹, Micaela Fredi², Chiara Bazzani¹, Maria Grazia Lazzaroni³, Melissa Fernandes⁴, Cecilia Nalli³, Angela Tincani³ and Franco Franceschini², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Autoimmune Unit/Internal Medicine Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (C.H.L.C), Lisbona, Portugal
Background/Purpose: Vedolizumab (VDZ) is a monoclonal antibody approved for inflammatory bowel disease, with a gut-specific mechanism of action, binding to α4β7 integrine expressed on gut-homing…
Abstract Number: 1503 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Axial Spondyloarthritis in Israel
Sara Borok Lev-Ran¹, Hagit Sarvagyl-Maman², Victoria Furer³, Sara Pel⁴, Iddo Drukman⁵, Gideon Flusser⁵ and Ori Elkayam⁶, ¹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ²Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Sourasky Medical Center, Tel Aviv, Israel, ⁵Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].